Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

Next Previous
Trial Profile

A Phase 1 Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Lorlatinib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Pfizer

    • Most Recent Events

    • 29 Nov 2018 Planned End Date changed from 24 Aug 2022 to 6 Jul 2022.
    • 29 Nov 2018 Planned primary completion date changed from 24 Aug 2022 to 25 Jan 2022.
    • 29 Nov 2018 Planned initiation date changed from 11 Jan 2019 to 12 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top